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Abstract
Background:  The aims of this study were to identify that the dif-
ferences in the natural history of patients with symptomatic and 
asymptomatic carotid stenosis may be reflected in differences in the 
expression of procoagulant protein factors.
Methods: Carotid artery plaques were obtained from 33 symp-
tomatic and 4 asymptomatic patients with internal carotid artery 
stenosis  of  greater  than  70%.  These  plaques  were  stained  with 
monoclonal antibody against human tissue factor. Areas of staining 
for the cap and core were analysed using the analySIS computer 
programme. 
Results: There were 37 patients, of whom 27 were male with a 
mean age 69.3 years and a range of 53 to 83 years. Statistical anal-
ysis using non-parametric tests revealed a significant increase in 
the area of positive staining for tissue factor in plaques taken from 
symptomatic patients when compared to those who were asymp-
tomatic (P = 0001). Within the symptomatic patients group there 
was significantly increased tissue factor in the plaque core of those 
who were the most recently symptomatic (P = 0.003). 
Conclusions: The unstable carotid artery plaque is associated with 
significantly increased tissue factor expression in the cap and core. 
Plaques from the most recently symptomatic patients have signifi-
cantly more tissue factor in the core and this may represent part 
of the mechanism responsible for plaque destabilisation. More re-
search is needed in this important area.
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Introduction
  Stroke is the third commonest cause of death in the UK 
after coronary disease and cancer, and the principal cause 
of neurological disability [1]. The annual UK incidence of 
stroke is 2:1000 and each year 125000 patients will suffer 
their first stroke [2]. Half of strokes affect patients over 75 
years and only 25% occur in patients under the age of 65 [1]. 
Stroke patients in the UK utilise 10% of hospital bed-days 
and 5% of annual health expenditure [3]. Stroke mortality 
within the UK decreased by up to 20% over the last 30 years 
[4]. However, because of an increase in the ageing popula-
tion, the overall incidence of stroke could increase by up to 
30% by 2033 [5]. The vast majority of strokes are ischaemic, 
of these 80% affect the carotid territory. 
 The commonest cause of ischaemic stroke is throm-
boembolism of the internal carotid artery (ICA). Stenoses 
develop at the origin of the ICA because this is a complex 
region with haemodynamic phenomena compromising low 
shear stress, flow stasis and flow separation that predispose to 
atherosclerotic plaque formation. Should the plaque undergo 
acute  change  (rupture,  ulceration,  or  intraplaque  haemor-
rhage), the inner core of thrombogenic subendothelial col-
lagen is exposed and this predisposes towards the formation 
of thrombus and the onset of symptoms [6].
 
Carotid artery disease
  The carotid artery plaque is a dynamic structure. It may 
be stable and unlikely to produce symptomatic embolization 
and carotid occlusion or conversely, while not necessarily 
being any more stenotic, unstable and at high risk of produc-
ing symptomatic embolization or carotid occlusion [7].
 
Mechanism of stroke in symptomatic carotid artery disease
   The majority of strokes are due to embolization from an 
atherosclerotic plaque or acute occlusion of the carotid artery 
and propagation of thrombus distally [7], however a small 
number of strokes can be attributed to hypoperfusion [8]. 
Low flow alone is not usually sufficient to cause ischaemic 
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stroke distal to symptomatic carotid stenosis. Post-stenotic 
narrowing may be protective because low blood flow distal 
to the stenosis is insufficient to carry emboli to the brain [9].
 
Relationship between presenting symptoms and stroke
 Risk factors for an ischaemic stroke include: sex, in-
creasing age, smoking, hypertension, ischaemic heart dis-
ease,  cardio-embolic  source,  peripheral  vascular  disease 
and diabetes [6]. Presenting symptoms significantly predict 
outcome after carotid endarterectomy (CEA). Patients with 
amaurosis fugax (AF) have a significantly better survival 
than those with transient ischaemic attacks (TIA’s), transient 
strokes or progressive strokes [10]. A history of crescendo 
TIA’s and being female are associated with an increased in-
cidence of perioperative death and stroke within 30 days of 
the operation. Deaths between 1 and 36 months are associ-
ated with both ischaemic heart disease and diabetes in both 
sexes [10]. 
 
Carotid atherosclerotic plaque morphology
    Angiographic plaque surface morphology is used along 
with the degree of carotid stenosis to identify patients most 
likely to benefit from CEA and other preventive treatment 
[11]. MRI angiography, CT scans and colour coded duplex 
ultrasonography are now very reliable diagnostic techniques 
and have largely superseded routine arterial angiography for 
surgical planning [12]. Biasi et al recently showed a rela-
tionship between plaque echogenicity and stroke risk. His 
study demonstrated that the grey scale median of a plaque, 
measured using a computerised method is associated with 
the presence or absence of CT-brain infarction. Plaques with 
high grey scale median (echogenic) were associated with an 
11% incidence of CT-brain infarction, whereby plaques with 
low grey scale median (echolucent) were associated with a 
55% incidence of CT-brain infarction [13]. Previous studies 
have already suggested that the presence of CT-brain infarcts 
is a risk factor for subsequent stroke and death [14-17].
 
Cellular biology and plaque rupture
  Previous histological examinations have demonstrated 
subtle  differences  in  the  characteristics  of  atherosclerotic 
plaque removed from symptomatic patients. In symptomatic 
patients inflammation is more common, with greater num-
ber of macrophages and T cells detected in the cap of the 
symptomatic plaque [18-20]. The necrotic core is also placed 
nearer to the fibrous cap and the minimum cap thickness is 
less [7].
 Smooth muscle cells lay down collagen, the principal 
connective tissue component of the fibrous cap. Collagen 
breakdown is dependant on the balance between proteolytic 
enzymes; matrix metallaproteinases (MMP’s) and their in-
hibitors;  tissue  inhibitors  of  metalloproteinases  (TIMP’s).   
High levels of MMP’s have been demonstrated at the site 
of the inflammatory infiltrate in the fibrous cap [21], smooth 
muscle cell apoptosis has also been demonstrated in unstable 
carotid plaques [22]. 
 T-cells secrete CD-40 and interleukin-1 (IL-1), which 
activate macrophages which in turn stimulate the apoptotic 
activity of MMP’s resulting in collagen degradation [7].
 
Plaque thrombogenicity
 On plaque rupture, exposure of the necrotic core to 
circulation promotes thrombosis. This appears to be an im-
portant mechanism of plaque progression, in addition to em-
bolization. Increased expression of tissue factor, the most im-
portant stimulant of the extrinsic clotting cascade, has been 
demonstrated in plaques from patients with unstable angina 
or myocardial infarction [23]. In an animal model, plaque 
rupture is associated with increased tissue factor production 
from circulating monocytes, which is reduced by treatment 
with a nitrous oxide precursor [24].
 
Tissue factor (TF)
  TF is a 47-kD membrane bound, low weight molecular 
glyco-protein essential for the activation of the extrinsic co-
agulation pathway. TF receptor is a member of the class 2 cy-
tokine receptor super-family. Growth factors and cytokines 
present in vascular smooth muscle cells and macrophages 
regulate the TF expression [25]. 
 TF complexes with factors VII and VIIa, permitting 
enzymatic activation of factors X and IX, the substrates for 
factor VIIa [26], and ultimately leading to the generation of 
thrombin [26]. TF is strongly induced in activated inflam-
matory macrophages and T cells. By its ability to bind factor 
VIIa; TF directly activates the coagulation cascade. There-
fore, TF is a candidate molecule linking plaque inflammation 
with arterial thromboembolism. In the present study, we car-
ried out an immunocytochemical analysis of TF expression 
in endarterectomy specimens from 37 patients undergoing 
CEA for high-grade ICA stenosis and addressed the relation-
ship of TF expression to clinical features of plaque instabil-
ity.
 
Subjects and Methods
 
Patients
 The study included 37 surgical in-patients enlisted to 
undergo CEA for high-grade ICA stenosis (≥ 70% luminal 
narrowing). The study was approved by the local ethics re-
view committee and performed in accordance with institu-
tional guidelines. Informed consent was obtained from all 
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patients. Baseline characteristics of the study population are 
provided in Table 1. The degree of stenosis was determined 
by Standardised Imaging and Doppler Criteria for Cerebro-
vascualr Diagnosis using Duplex Sonography [27]. During 
surgery intra-venous heparin was given to all patients as an 
anti-coagulant.
 
Histological procedure and immunocytochemistry
  After longitudinal arteriotomy, the carotid atheroscle-
rotic plaque was excised en bloc (routine endarterectomy), 
fixed  immediately  in  buffered  formalin,  decalcified,  and 
transversely sectioned at 5-mm intervals [28]. Each 5-mm 
tissue bloc was embedded separately into paraffin. For im-
munocytochemistry,  3-mm  sections  were  mounted  onto 
gelatine-coated slides. After deparaffinization, sections were 
incubated with monoclonal antibody (mAb) against human 
tissue factor (No.4508, American Diagnostica Inc) at 1:200 
dilution, followed by goat anti-mouse (Vector Laboratories) 
and the ABC ELITE kit reagents (Vector) with diaminoben-
zidine as a substrate. For antigen retrieval all sections were 
microwaved in 10mmol/L sodium citrate buffer, pH 6.0, for 
10 minutes before staining.
 Absence of tissue factor antibody was regarded as a 
negative control, while a positive control was the presence of 
tissue factor antibody in a human colon cancer tissue. May-
er’s hematoxilyn was used to counter-stain all the sections to 
enable the histopathologist to review the slides. 
 
Quantification
  The analySISTM computer program was used to calcu-
late the total area of positive TF staining within the cap and 
core of each specimen. 
 
Statistical Analysis
  Paired sample T-tests were not used to analyse the data, 
as it was not normally distributed  (v values of the Shapiro-
Francia W normality test were outside the range of 2.0-2.8, 
v value of cap = 3.6, v value of core = 1.8). The non-para-
metric Mann-Whitney U  test  was  used  to  investigate the 
relationship between the extent of TF expression (median 
TF+ section area in the cap and core of each plaque) and 
the occurrence of ischaemic symptoms. Kruskal-Wallis non-
parametric test was used to study the relationship between 
TF expression (median TF+ section area in the cap and core 
of each plaque) and the time since symptoms. P values of 
< 0.05 were considered indicative of statistically significant 
findings. Measurement errors were calculated to account for 
the natural variation of the measurement process using the 
repeatability method [29]; values calculated were not signifi-
cant (mean difference = 915.4, mean within-subject standard 
deviation = 647.3).
 
Results
  TF expression was found in all plaques, however there 
was a significant difference in the area of positive staining in 
plaques from symptomatic (Fig. 1) and asymptomatic (Fig. 
Age (mean ± SD) Sex (Male)
All Patients (n=37) 69 ± 7 27
Asymptomatic (n=4) 72 ± 4 1
Symptomatic (n=33) 69 ± 9 26
Time Since Symptoms Number Sex (Male)
       Asymptomatic 4 1
       1-6 Months 17 16
       < 1 Month 16 10
Type of Symptoms Number Sex (Male)
       Asymptomatic 4 1
       TIA/AF 26 5
        Stroke  7 21
Table 1. Clinical features of symptomatic and asymptom-
atic patients with high-grade ICA stenosis (≥70%)
Figure 1. Diffuse TF immuno-reactivity in the core of a symp-
tomatic patient.
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2) patients. The resulting P values (Table 2) correspond to 
Mann-Whitney U non-parametric test with units of mm2 ex-
pressing the median and the interquartile range. (Fig. 3, 4)
  The patients were then divided into groups according 
to the length of time between the last acute event and the 
CEA. Using the Kruskal-Wallis non-parametric test (Table 
3); the expression of TF in the core was shown to be sig-
nificantly increased in plaques from the most recently symp-
tomatic patients. (Fig. 5).
Discussion
  
  In this study we have shown that in the most recently 
symptomatic carotid artery plaque there is an increased ex-
pression of TF when compared to the asymptomatic carotid 
artery plaque. Most TF immuno-reactivity was localised dif-
fusely in the acellular necrotic core and in regions within the 
atheroma’s fibrous cap. Our data therefore strongly suggest 
that TF induction at various regions of the plaque may play 
an important role in the destabilisation of high-grade ICA 
stenosis.
  The mechanism responsible for thrombus formation 
associated with ruptured atherosclerotic plaques is not well 
understood. One widely held view is that rupture or fissur-
ing of an atherosclerotic plaque results in exposure of col-
lagen and other extracellular proteins to blood-borne plate-
lets, which adhere to these elements via specific receptors 
and become activated [30]. Activated platelets release ADP 
and thrombin, bind fibrinogen, and activate other platelets, 
thereby producing local thrombosis in and on the arterial 
wall [25]. 
  Exposure of TF activity to coagulation factors may ei-
ther occur directly at the intimal surface or may result from 
plaque rupture leading to the release of macrophage-bound 
or extracellular material from deeper parts of the plaque to 
the blood stream [31]. The rupture of complicated plaques 
has been suggested to be due to the expression of MMP’s 
that degrade extracellular matrix components and thereby 
weaken the fibrous cap [21, 32]. A recent study by Loftus 
et al [33] showed a correlation between MMP-9 expression 
and carotid plaque destabilisation. Thus, it is an intriguing 
hypothesis that the concerted action of MMP-9 and TF may 
be a key mechanism of plaque destabilisation in cerebrovas-
cular disease patients who are at high risk of stroke.
 TF pathway inhibitor (TFPI) is found in vascular en-
dothelium and smooth muscle cells as well as in platelets, 
blood monocytes, and macrophages [34, 35].  It provides 
physiological inhibition of TF-initiated coagulation by bind-
ing to factors Xa and the TF-factor VIIa complex in a 2-step 
process. In atherosclerotic carotid arteries, TF expression is 
abundant, whereas TFPI expression is limited in up to 30% 
of plaques, resulting in predominant TF activity [36].
  Evidence also suggests that TF may have a variety of 
other actions in addition to initiating thrombin formation. 
For example, TF: VIIa induces the activation of mitogen-
activated protein kinase (MAP-Kinase) in a baby hamster 
kidney [37] and evokes intracellular Ca+2 mobilisation in 
human endothelial cells [38], which may lead to cell prolif-
eration. 
  Human atherosclerotic plaque tissue from CEA speci-
mens express TF messenger-RNA and protein in a few inti-
mal smooth muscle cells, as well as in a few macrophage-
like cells adjacent to cholesterol clefts [25]. Wilcox et al [39] 
showed that TF antigen seemed to occur extracellularly. An-
nex et al [40] demonstrated antigenic TF in coronary ather-
ectomy specimens but, as with previous immunohistochemi-
cal studies, TF was seen in only approximately one third of 
specimens.  When using digoxigenin labelled factors VIIa 
and X, Thiruvikraman et al [25] showed diffuse TF activity 
both intracellularly (endothelial cells, smooth muscle cells, 
Figure 2.  Diminished TF immuno-reactivity in the core of an 
asymptomatic patient.
Asymptomatic Symptomatic
P 
Value
TF Cap
379.1  
(301.4-703.2)
37296.2  
(32067.6-43648.7)
0.001
TF Core
399.8  
(282.2-710.4)
52689.2  
(39798.5-70827.0)
0.001
*All units are mm2 and expressed as a median (interquartile range).
Table  2.  TF  positive  staining  area  in  asymptomatic  and 
symptomatic Patients
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and macrophages) and extracellularly (lipid-rich core and fi-
brous matrix) in virtually all human atherosclerotic plaques 
taken from various sites.
 A potential limitation of our study arises from the fact 
that the sensitive immuno-histochemical staining procedure 
used for the detection of TF antigen does not allow direct 
conclusions with respect to the actual presence of TF bio-
activity. However in a comparative study, Jander et al [31] 
used a similar TF-specific antibody for the in-situ detection 
of TF and observed essentially identical staining patterns 
with a similar type of detection reagent; TF specific antibody 
bound to the atheroma’s acellular lipid core. It is therefore 
likely that the TF immuno-reactivity detected in our study 
indeed reflects TF binding activity for its physiologically rel-
Figure 3. Scatter Plot of TF positive staining area in the Plaque Cores of Asymptomatic and Symptomatic Patients (units 
are expressed in µm2).
Figure 4. Scatter Plot of TF positive staining area in the Plaque Caps of Asymptomatic and Symptomatic Patients (units are 
expressed in μm2).
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evant ligands. However, additional studies using TF bioas-
says will be necessary to definitively clarify the role of TF in 
ICA plaque destabilisation.
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